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Our work has shown that following focal ischemic lesion in adult
rats, neutralization of the axon growth inhibitor Nogo-A with the
monoclonal antibody (mAb) IN-1 results in functional recovery.
Furthermore, new axonal connections were formed from the
contralesional cortex to subcortical areas corresponding to the
observed functional recovery. The present study investigated
whether dendritic changes, also known to subserve functional
recovery, paralleled the axonal plasticity shown after ischemic
lesion and treatment with mAb IN-1. Golgi--Cox-stained layer V
pyramidal neurons in the contralesional sensorimotor cortex were
examined for evidence of dendritic sprouting. Results demonstrated
increased dendritic arborization and spine density in the mAb IN-1-
treated animals with lesion. Interestingly, administration of mAb IN-
1 without lesion resulted in transient dendritic outgrowth with no
change in spine density. These results suggest a novel role for
Nogo-A in limiting dendritic plasticity after stroke.
Keywords: dendritic arbors and spines, Golgi--Cox, layer V,
motor cortex, rat, stroke
Introduction
Ischemic stroke, the lack of blood ﬂow to the brain, is the third
most common cause of death in developed countries. One-third
of the 4.6 million stroke survivors in the USA are left perma-
nently disabled, thus representing the leading cause of serious
long-term neurological disability (American Heart Association,
2004). Neuronal loss due to stroke may result in chronic
impairment of sensory and motor function that is resistant to
therapeutic strategies.
Incomplete functional recovery after injury to the adult
central nervous system (CNS) is a result of the inability of
central neurons to form correct axonal and dendritic connec-
tions through regenerative or plastic responses. The failure of
adult neurons to establish new connections after CNS lesions is
most likely not an intrinsic deﬁcit in the growth potential of the
central neuron (Richardson et al., 1980; David and Aguayo,
1981), but rather an effect of the non-permissive adult environ-
ment. A major contributor to the presence of growth-inhibitory
proteins that creates a non-permissive environment and limits
the structural plasticity of injured mature neurons is CNSmyelin
(Schwab and Caroni, 1988; Qui et al., 2000). Several myelin-
associated proteins and chondroitin-sulfate proteoglycans
(CSPGs) have been characterized as inhibitors of axonal growth:
oligodendrocyte myelin glycoprotein (OMgp) (Wang et al.,
2002), myelin-associated glycoprotein (MAG) (McKerracher
et al., 1994; Mukhopadhyay et al., 1994), Nogo-A (Spillman
et al., 1997; Chen et al., 2000; GrandPre et al., 2000; Prinjha
et al., 2000), and the CSPGs Versican V2 (Schweigreiter et al.,
2004) and Brevican (Schmalfeldt et al., 2000). Nogo-A is
expressed in oligodendrocytes and myelin, and in certain
neuronal populations (Caroni and Schwab, 1988a; Chen et al.,
2000; Huber et al., 2002; Buss et al., 2004; Dodd et al., 2005; this
study). Based on several regeneration and plasticity studies,
Nogo-A has proven to be a powerful inhibitor of axonal growth
(for review, see Schwab, 2004). Regeneration studies have
supported this inhibitory role by neutralization of Nogo-A
with the speciﬁc antigen, monoclonal antibody (mAb) IN-1
(Fiedler et al., 2002) with in vitro growth assays (Caroni and
Schwab, 1988b) and in vivo spinal cord injury studies (Schnell
and Schwab, 1990; Bregman et al., 1995). Important to the
present study, intraventricular administration of mAb IN-1
resulted in axonal plasticity of intact ﬁber tracts after cortical
aspiration lesion (Kartje et al., 1999; Wenk et al., 1999) and
improved functional recovery of skilled movements after
unilateral pyramidotomy (Thallmair et al., 1998; Z’Graggen
et al., 1998), cortical aspiration lesion (Emerick and Kartje,
2004) and permanent middle cerebral artery occlusion (MCAO)
(Papadopoulos et al., 2002; Seymour et al., 2005) in adult rats.
Clinical studies have implicated the contralesional cortex as
an important contributor to motor recovery after stroke
(Cramer et al., 1997; Cuadrado et al., 1999). Functional imaging
studies demonstrated increased cerebral blood ﬂow (Weiller
et al., 1993) as well as altered patterns of activation (Feydy et al.,
2002; Johansen-Berg et al., 2002) in the intact cerebral hemi-
sphere of human patients recovering from unilateral stroke that
paralleled functional recovery. Our past work has demonstrated
the critical role in functional recovery for neuronal (axonal)
plasticity originating from the contralesional hemisphere to
re-innervate deafferented areas after cortical lesions and treat-
ment with mAb IN-1 (Wenk et al., 1999; Kartje et al., 1999;
Papadopoulos et al., 2002). Also, using intracortical micro-
stimulation mapping techniques, our laboratory has shown
that reorganization in the contralesional forelimb motor cortex
parallels functional recovery after aspiration lesion and treat-
ment with mAb IN-1 (Emerick et al., 2003). Since dendritic
plasticity is also associated with functional recovery after
cortical lesions (Jones and Schallert, 1994; Kawamata et al.,
1997b; Rowntree and Kolb, 1997; Biernaskie et al., 2004), we
questioned whether neuronal (dendritic) changes paralleled
the axonal plasticity shown after stroke and treatment with
mAb IN-1. Therefore, we analyzed the dendritic arbors of layer V
pyramidal neurons within the forelimb motor cortex of the
contralesional hemisphere using a modiﬁed Golgi--Cox staining
procedure. Our results demonstrate a dramatic increase in both
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the apical and basilar dendritic arborization and spine density of
pyramidal neurons in the stroke/mAb IN-1-treated group com-
pared with controls. These results point to a role for Nogo-A in
restricting dendritic plasticity after stroke.
Materials and Methods
Animals and In Vivo Manipulations
Adult male Long Evans, black-hooded rats (250--360 g) were divided into
eight experimental groups: (i) MCAO only, six-week survival (n = 6); (ii)
MCAO plus mAb IN-1, six-week survival (n = 6); (iii) MCAO plus control
antibody treatment, six-week survival (n = 5); (iv) mAb IN-1 only, two-
week survival (n = 5); (v) mAb IN-1 only, six-week survival (n = 3); (vi)
control Ab only, two-week survival (n = 4); (vii) control Ab only, six-
week survival (n = 3); and (viii) normal animals (n = 5). Animals were
number-coded and investigators were blinded to the treatment groups.
Experiments were approved by the Institutional Animal Care and Use
Committees of Loyola University/Hines VA.
MCAO was performed as described in Chen et al. (1986). Animals
were anesthetized with sodium pentobarbital (50 mg/kg, i.P.). Bilateral
common carotid arteries (CCA) were isolated, a vertical 2 cm long
incision was made between the eye and ear, and the temporalis muscle
was retracted. A burr hole was made to expose the left MCA and it was
permanently occluded with a 10-0 suture. The CCA ipsilateral to the
MCAO was permanently occluded with a 4-0 suture and the contralat-
eral CCA was temporarily occluded for 45 min. Body temperature was
maintained with a heating pad and monitored with a rectal probe. The
wounds were then closed and animals warmed under a heating lamp
until awake.
Antibody application was performed immediately after MCAO as in
our previous study (Papadopoulos et al., 2002). A cell suspension (6 ll)
containing a total of 1 3 105 of either mAb IN-1 (Caroni and Schwab,
1988b) or the control antibody (anti-HRP) (Schnell and Schwab, 1990)
secreting mouse hybridoma cells was injected posterior to the lesion (4
mm caudal, 5 mm lateral and 5 mm ventral to bregma) on the side of the
lesion. MCAO only animals received vehicle only injections in the same
coordinates. All animals, including those in the MCAO only group,
received cyclosporin A (10 mg/kg, i.P.) daily starting from the day
before surgery to 7 days after surgery to prevent rejection of the
hybridoma xenograft.
Histology
Either 2 or 6 weeks after MCAO and/or antibody treatments, animals
were overdosed with sodium pentobarbital (100 mg/kg, i.P.) and
transcardially perfused with 0.9% saline. Brains were removed and
immersed whole in Golgi--Cox solution (Glaser and van der Loos, 1981)
for 14 days and then placed in 30% sucrose solution for 2 days. Brains
were cut into 200 lmcoronal sections using a vibratome, slide mounted,
and reacted according to the procedure described by Gibb and
Kolb (1998).
Stroke Volume Analysis
The stroke volume was quantitatively analyzed on Golgi--Cox stained
sections (+4.7 to –5.2 mm from bregma according to Paxinos and
Watson, 1998) using a computer-interfaced imaging system (NIH Image
1.51) by the method as described in Kawamata et al. (1997a) (total area
of the intact contralateral hemisphere -- total area of the intact ipsilateral
hemisphere multiplied by the total distance between the sections).
Stroke size was expressed as a percentage of the intact contralateral
hemispheric volume.
Nogo-A Immunostaining
A rat was euthanized and perfused intracardially with 0.9% saline and 4%
paraformaldehyde. The brain was removed and ﬂash frozen in isopen-
tane, then stored in a –80C freezer until cutting. Sections were cut at 50
lm on a freezing microtome and placed into tris-buffered saline (TBS).
For immunohistochemistry, sections were ﬁrst treated with a blocking
solution of 10% normal goat serum (NGS)/TBS/0.5% Triton-X for 60min.
Sections were then incubated in TBS containing 0.5% Triton-X, 5% NGS,
a rabbit polyclonal anti-Neuroﬁlament 200 (1:250; Sigma, St Louis, MO)
and the mouse IgG 11C7, a monoclonal antibody speciﬁc for Nogo-A
(1:500; Novartis, Basel, Switzerland), overnight at 4C. Sections were
rinsed thoroughly and incubated in TBS containing 0.5% Triton-X, 5%
NGS, a tetramethylrhodamine-conjugated goat anti-rabbit IgG (1:1000;
Molecular Probes, Eugene, OR) and an AlexaFluor 488-conjugated goat
anti-mouse IgG (1:1000; Molecular Probes) for 60 min at room
temperature. After rinsing, sections were incubated in a 300 nM solution
of 49-6-diamidino-2-phenylindole (DAPI) in 0.1% Triton-X/TBS for 30
min. After a ﬁnal rinse, sections were mounted onto slides from dilute
TBS solution and coverslipped with the aqueous mounting medium
Fluoromount-G (Electron Microscopy Sciences, Hatﬁeld, PA).
Neuroanatomical Analysis
Seven layer V pyramidal neurons per animal located within the forelimb
motor cortex and ﬁve layers II/III pyramidal neurons per animal located
within the occipital cortex of the contralesional hemisphere were
identiﬁed with an atlas (Zilles, 1985) and according to previous
electrophysiological studies (Neafsey et al., 1986). Criteria for inclusion
in the analyses were that the neuron had to be well impregnated,
unobstructed by other dendrites, blood vessels or glial cells, and the
dendritic arborizations intact and visible in the plane of section. For all
analyses the slides were coded and investigators were blind to the
treatment group.
Apical and basilar dendrites of layers II/III and V pyramidal neurons in
the intact hemisphere opposite the lesion were traced at 325
magniﬁcation with the aid of a camera lucida drawing tube. Both apical
and basilar dendritic trees were analyzed for total dendritic length
(Sholl, 1956) and total number of branch segments within a branch
order (Coleman and Riesen, 1968). Branch order was determined by
considering that branches emanating directly from the cell body
(basilar) or the primary apical dendrite were ﬁrst order; once bifurcation
occurred, two secondary dendrites were formed and so on.
Dendritic spine densities were analyzed from layer V pyramidal
neurons within the forelimb motor cortex of the intact hemisphere.
Using a 3100 oil immersion lens, a 50 lm length of one terminal basilar
branch segment of third or higher order and one terminal apical
segment from the midpoint of the apical tree were drawn from seven
neurons per animal. Spine density was expressed as the number of
spines per lm. All the data presented in this study are expressed as
means ± SEM. Statistical comparison for layer V and layers II/III neurons
was assessed by one-way analysis of variance (ANOVA) followed by
Newman--Keuls test for post hoc analyses.
Results
Lesions are Localized in the Sensorimotor Cortex
The topographical location of all lesions included the sensori-
motor cortex ipsilateral to the occluded MCA (Fig. 2A, shaded
area) with minimal subcortical damage. Measurement of the
infarct volumes showed no difference between the stroke only
(16.46 ± 5.01), stroke/control antibody (13.82 ± 3.98) and
stroke/mAb IN-1 groups (11.70 ± 1.91) (P = 0.58, one-way
ANOVA).
Forelimb Cortex Layer V Neurons are
Strongly Nogo-A Positive
Immunohistochemical staining with the Nogo-A speciﬁc mouse
monocloncal antibody 11C7 (labeled with a green ﬂuorophore)
and a rabbit polyclonal against the neuronal structural protein
Neuroﬁlament 200 (labeled with a red ﬂuorophore) revealed
that the inhibitory protein Nogo-A is present in many neurons
across cortical layers II through VI of rat forelimb cortex (FL), as
evidenced by the overlap of green and red ﬂuorescence in the
processed tissue (Fig. 1A). The cell body and dendritic processes
of the large layer V pyramidal neurons stain very robustly for
Nogo-A, but there is no visible staining in the nucleus (Fig. 1B).
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Dendritic Complexity is Enhanced after Stroke and
mAb IN-1 Treatment
The signiﬁcant functional recovery and increased axonal
plasticity observed previously in rats after stroke and immediate
or delayed mAb IN-1 treatment (Papadopoulos et al., 2002) led
us to investigate whether dendritic changes paralleled these
events. Both apical and basilar dendritic arborizaton and spine
densities of Golgi--Cox stained layer V pyramidal neurons within
the intact, contralesional forelimb motor cortex were examined
(Fig. 2A, boxed area). Representative camera lucida drawings of
pyramidal neurons from stroke only, stroke/control antibody
and stroke/mAb IN-1 treatment groups are shown in Figure 2B--
D. Apical dendrite patterns in animals with stroke lesion only, in
stroke animals treated with control antibody and in normal
animals showed no statistical difference between groups.
However, stroke animals with mAb IN-1 treatment were
signiﬁcantly different from all control groups (Fig. 3A,C,D).
mAb IN-1-treated animals had signiﬁcantly greater apical den-
drite arborization when measured for the number of branch
segments within branch orders (Fig. 3A), total number of
branches (P < 0.001, Fig. 3C) and dendritic length (P < 0.01,
Fig. 3D).
As with apical dendritic arborization, a similar pattern in
basilar dendrites was observed. While the control groups
showed no signiﬁcant difference from each other, the stroke/
mAb IN-1-treated animals showed an increased basilar arbor
complexity when compared with controls. Analyses demon-
strated that the stroke/mAb IN-1-treated group had signiﬁcantly
greater number of branch segments per branch order (Fig. 3B),
total number of branches (P < 0.001, Fig. 3C) and dendritic
length (P < 0.001, Fig. 3D).
Quantitative analysis of spine densities in layer V pyramidal
neurons of the contralesional forelimb motor cortex showed
a signiﬁcant increase in the number of spines of both apical and
basilar terminal branch segments in stroke animals treated with
mAb IN-1 when compared with stroke only, stroke/control Ab
and normal groups (P < 0.001, Fig. 4).
Lasting Enhanced Dendritic Complexity is Speciﬁc to
the Motor Cortex after Stroke and mAb IN-1 Treatment
The signiﬁcant dendritic plasticity observed in the contrale-
sional forelimb motor cortex of stroke/mAb IN-1 animals raises
the question whether the effect on plasticity is speciﬁc to an
area or is found globally throughout the cortex. To determine
this, we assessed the dendritic structures in the lateral area of
the secondary visual cortex (Oc2L), a distant region from the
motor cortex. Apical and basilar dendritic arbors of layers II/III
neurons within the contralesional occipital cortex were exam-
ined. Quantitative analysis demonstrated no difference in
occipital neuron total dendritic length between the stroke/
mAb IN-1 group, normal animals, and normal animals treated
with mAb IN-1 at 6 weeks (P > 0.05, Fig. 5). However, total
dendritic length was enhanced after 2 weeks of mAb IN-1
treatment in normal animals, but this difference resolved at
6 weeks (P < 0.05).
Dendritic Complexity is Transient after
mAb IN-1 Treatment in Normal Animals
Treatment with mAb IN-1 in the absence of CNS injury induces
transient axonal outgrowth in adult cerebellar Purkinje neurons
(Buffo et al., 2000) and corticospinal neurons (Bareyre et al.,
2002). We therefore investigated whether mAb IN-1 adminis-
tration without stroke had the same effect on dendritic out-
growth. Apical and basilar dendritic arbors and spine densities
of layer V pyramidal neurons within the forelimb motor cortex
were examined.
At 2 weeks after antibody administration, control antibody-
treated animals showed no increase in dendritic complexity
when compared with stroke/mAb IN-1 animals in all parameters
measured (P < 0.01) (Fig. 6A,B). Conversely, the dendritic
arbors of mAb IN-1-treated animals were similar to those of
stroke/mAb IN-1 animals in both total number of branches
(Fig. 6A) and length (Fig. 6B), showing an overall increase in
dendritic outgrowth. Despite this effect on dendrite growth,
spine density in mAb IN-1-treated animals without stroke
remained unaffected by antibody treatment. This was signiﬁ-
cantly different to stroke/mAb IN-1-treated animals that
showed more spines per dendritic length (P < 0.001) (Fig. 6C).
At 6 weeks after antibody administration, animals treated with
mAb IN-1 were similar to control antibody-treated animals in
dendritic length and total branch number when compared with
the increased dendritic complexity of stroke/mAb IN-1-treated
animals (P < 0.01) (Fig. 6A,B). This indicated that the dendritic
growth triggered by mAb IN-1 alone without stroke at 2 weeks
was transient over time. In addition, spine density remained
unaffected in mAb IN-1-treated animals when compared with
the increased density in the stroke/mAb IN-1 animals (P <
0.001) (Fig. 6C).
Figure 1. Nogo-A is expressed on layer V pyramidal neurons in cortical area FL in the rat. (A) Low magnification (332) view of Nogo-A (green), Neurofilament 200 (NF200; red)
and DAPI (blue) in the cortical layers of area FL. Nogo-A staining is most robust on the large pyramidal neurons in layer V. Box represents the approximate field shown in (B).
Scale bar 5 500 lm. (B) Layer V pyramidal neurons staining positively for Nogo-A (green) and NF200 (red). Scale bar 5 30 lm.
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Discussion
The present study demonstrates that treatment with the mAb
IN-1 to neutralize Nogo-A after stroke in adult rats results in
a signiﬁcant increase in the dendritic arbors and spine density of
layer V pyramidal neurons within the forelimb motor cortex of
the opposite, intact hemisphere. Additionally, analysis of mAb
IN-1-treated animals without lesion revealed a transient in-
crease in dendritic arborization of layer V pyramidal neurons
with no increase in spine density. An increase in neuronal
complexity as seen here has been correlated with improved
motor function in animals after cortical lesions (Jones and
Schallert, 1994; Kawamata et al., 1997b; Rowntree and Kolb,
1997; Biernaskie et al., 2004). Importantly, strategies such as
enriched environment and drug intervention have been shown
to enhance dendritic plasticity and lead to better functional
outcome (for review, see Kolb and Metz, 2003).
In recent years, Nogo-A has been identiﬁed as a primary
inhibitor of axonal growth after injury in the adult CNS. Indeed,
our earlier work has shown that neutralizion of Nogo-A with the
mAb IN-1 resulted in axonal plasticity from cortical neurons
Figure 2. Qualitative assessment of increased apical and basilar dendritic arbor complexity in stroke/mAb IN-1-treated rats. (A) Schematic diagram illustrating a typical lesion
(shaded area) after permanent MCAO. The location of the affected area includes the sensorimotor cortex. Boxed area indicates the contralesional forelimb motor cortex from which
layer V pyramidal neurons were analyzed. (B--D) Representative camera lucida drawings of layer V pyramidal neurons respective of treatment condition, i.e. stroke only (B), stroke/
control Ab (C) and stroke/mAb IN-1 (D). All data shown (A--D) are from 6 weeks after stroke. Panel A modified and reprinted from The Rat Brain in Stereotaxic Coordinates (CD-
ROM), 5th Edition, George Paxinos and Charles Watson, p. 65, Copyright 2004, with permission from Elsevier.
Figure 3. Increased dendritic arbor complexity of layer V contralesional motor cortex neurons in stroke/mAb IN-1-treated rats. (A) Quantification of the total number of apical
branch segments within a particular branch order showing the mean of seven neurons per animal for each treatment group: stroke only (n56), stroke/control Ab (n5 5), stroke/
mAb IN-1 (n 5 6), and normal (n 5 5). Br, branch order. (B) Quantification of the total number of basilar branch segments within a particular branch order showing the mean of
seven neurons per animal for each treatment group: stroke only (n56), stroke/control Ab (n5 5), stroke/mAb IN-1 (n5 6) and normal (n5 5). Br, branch order. (C) Quantification
of the total number of branches within the apical and basilar arbors showing the mean of seven neurons per animal for each treatment group: stroke only (n56), stroke/control Ab
(n5 5), stroke/mAb IN-1 (n5 6) and normal (n5 5). (D) Quantification of total dendritic length showing the mean of seven neurons per animal for each treatment group: stroke
only (n56) (clear bars), stroke/control Ab (n5 5) (hatched bars), stroke/mAb IN-1 (n5 6) (black bars) and normal (n5 5) (gray bars). All data are represented as mean ± SEM.
*P\ 0.05; **P\ 0.01; ***P\ 0.001 (one-way ANOVA, Newman--Keuls test for post hoc comparison). All data shown (A--D) are from 6 weeks after stroke.
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in the opposite cerebral hemisphere after unilateral stroke
(Papadopoulos et al., 2002; Seymour et al., 2005) or aspiration
lesion (Emerick and Kartje, 2004). This axonal plasticity
paralleled the improved behavioral recovery on skilled motor
tests as observed in these animals. Using intracortical micro-
stimulation, we have recently shown that, following cortical
lesion and treatment with anti-Nogo-A antibody, cortical re-
organization occurred in the opposite, intact hemisphere
(Emerick et al., 2003). We now show an important role for
Nogo-A in regulating dendritic growth after ischemic stroke in
this contralesional hemisphere.
The dendritic plasticity observed in the present study may be
the result of a complexity of factors. Early events such as
physiological and molecular alterations may facilitate a growth
permissive environment after stroke. Alterations in physiolog-
ical properties have been shown to promote excitability by
disinhibition of the contralesional hemisphere after focal brain
injury in human subjects (Liepert et al., 2000; Manganotti et al.,
2002) and animal studies (Rouiller et al., 1994; Fabri and
Manzoni, 1996; Buchkremer-Ratzmann and Witte, 1997), and
facilitate the induction of synaptic plasticity (Carmichael
and Chesselet, 2002). In addition, the cortex opposite the
lesion has an increased expression of factors implicated in
plasticity such as the immediate early genes c-fos and nerve-
growth factor inducible-B (Johansson et al., 2000; Keyvani
et al., 2002), phosphorylated cAMP-response element (Tanaka
et al., 1999, 2001; Keyvani et al., 2002), and activity-regulated
cytoskeleton-associated protein, a protein enriched in dendrites
(Keyvani et al., 2002). Several neurotrophins are also up-
regulated in the hemisphere contralateral to the stroke lesion,
including nerve growth factor (Lee et al., 1996), insulin-like
growth factor (Garcia-Estrada et al., 1992) and basic ﬁbroblast
growth factor (Schallert et al., 2000). Moreover, the growth-
associated protein GAP-43 is up-regulated in the contralesional
hemisphere with a subsequent increase in synaptophysin levels,
suggesting the development of mature synapses (Stroemer
et al., 1995).
Dendritic structural events have also been reported in the
hemisphere opposite the lesion. After unilateral cortical elec-
trolytic lesions, dendritic sprouting in the contralesional cortex
was shown by an increase in the apical and basilar dendritic
complexity of layer V pyramidal neurons up to 18 days following
the lesion with a subsequent decrease by day 30 (Schallert and
Jones, 1993; Jones et al., 1996). However, others using electro-
lytic or aspiration lesions found no evidence of transient
Figure 4. Increased spine density of layer V contralesional motor cortex neurons in
stroke/mAb IN-1-treated rats. (A--D) Representative photomicrographs of dendritic
spines from layer V pyramidal neurons in the forelimb motor cortex respective of
treatment condition, i.e. normal (A), stroke only (B), stroke/control Ab (C), and stroke/
mAb IN-1 (D). Note the increased spine density in stroke/mAb IN-1 animals and their
apparently different morphology, i.e. many multi-headed spines when compared with
controls. Scale bar equals 10 lm. (E) Quantification of basilar and apical spine density
from a terminal branch segment showing the mean of seven branch segments per
animal for each treatment group: stroke only (n56), stroke/control Ab (n5 5), stroke/
mAb IN-1 (n 5 6) and normal (n 5 4). All data are represented as mean ± SEM.
***P \ 0.001 (one-way ANOVA, Newman--Keuls test for post hoc comparison).
All data shown (A--E) are from 6 weeks after stroke.
Figure 5. Lasting increased dendritic plasticity is specific to the contralesional motor
cortex after stroke/mAb IN-1. Quantification of total dendritic length from layers II/III
neurons in the occipital cortex showing the mean of five neurons per animal for each
treatment group: stroke/mAb IN-1 (six-week survival; n5 6), normal (n5 5), mAb IN-
1 only (two-week survival; n 5 5) and mAb IN-1 only (six-week survival; n 5 3). No
significant difference is shown in occipital neuron total dendritic length between the
stroke/mAb IN-1 group, normal animals and animals treated with mAb IN-1only at 6
weeks survival (P[ 0.05, Fig. 5). However, total dendritic length was significantly
enhanced in animals treated with mAb IN-1 only at two-week survival, indicating
a transient response of occipital neurons to treatment with mAb IN-1(P\ 0.05). All
data are represented as mean ± SEM. *P\0.05 (one-way ANOVA, Newman--Keuls
test for post hoc comparison).
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dendritic growth in the contralesional hemisphere (Forgie
et al., 1996; Prusky and Whishaw, 1996). In our study we
examined dendritic changes at 6 weeks post-stroke in order to
investigate a time point when any possible transient growth
would have returned to normal. Interestingly, in our study
normal animals treated with mAb IN-1 without stroke showed
a transient increase of dendritic arbors at 2 weeks that returned
to normal by 6 weeks post-treatment, indicating that Nogo-A
neutralization has an effect on dendritic plasticity that is not
dependent upon a coexisting cortical lesion.
We previously reported that treatment with mAb IN-1 or
other antibodies against Nogo-A increases cortico-efferent
plasticity from the opposite, forelimb motor cortex into deaf-
ferented motor areas with concomitant improved functional
outcome after pyramidotomy (Thallmair et al., 1998; Z’Graggen
et al., 1998), cortical aspiration lesions (Emerick and Kartje,
2004) and ischemic stroke (Papadopoulos et al., 2002; Wiessner
et al., 2003). Here we report that after unilateral stroke, animals
treated with mAb IN-1 showed a signiﬁcant increase in apical
and basilar dendritic growth and spine density in the same
population of layer V pyramidal neurons of the opposite,
forelimb motor cortex. These results implicate Nogo-A as
a ‘stop’ signal for both dendritic and axonal growth, since
neutralization with an anti-Nogo-A antibody leads to increased
dendritic arborization and spine formation. The physiological
mechanism responsible for the dendritic sprouting of these
same cortical neurons shown here is speculative. However, an
important hypothesis to note is that dendritic growth is
regulated by afferent innervation and synaptic contact in an
activity-dependent manner (Kossel et al., 1997; Engert and
Bonhoeffer, 1999; Maletic-Savatic et al., 1999; McAllister, 2000;
Whitford et al., 2002). Consequently, the robust axonal sprout-
ing observed after treatment with mAb IN-1 in previous studies
may provide the afferent innervation for the present dendritic
growth. Whether the activity originates from local axonal
collaterals in the homotopic cortex, from distant transcallosal
connections or from the combination of both has yet to be
determined.
Previous studies have shown that treatment with mAb IN-1 to
block Nogo-A in normal non-injured adult animals promoted
transient axonal sprouting of the CST (Bareyre et al., 2002) and
cerebellar Purkinje cells (Buffo et al., 2000). However, after
corticospinal tract injury and treatment with mAb IN-1, axonal
sprouting was target speciﬁc and stable, and was paralleled by
an increased expression of guidance molecules and growth-
related proteins (Bareyre et al., 2002). In the present study we
show that after stroke/mAb IN-1 treatment the increase in
dendritic complexity is stable and possibly responding to the
same mechanistic cues as axons. Similar to axonal studies in
non-injured animals, administration of mAb IN-1 in normal
animals without stroke resulted in transient growth of dendritic
length and branching which returned to normal by 6 weeks, and
showed no increase in the number of spines at any time.
Furthermore, our results show that the effect on dendrites is
not speciﬁc to motor neurons, i.e. the occipital neurons also
showed a transient effect from anti-Nogo treatment and
returned to normal at 6 weeks. Therefore, our effect of
sustained dendritic plasticity in the contralesional motor cortex
Figure 6. Transient increase in dendritic arbor complexity of layer V contralesional motor cortex neurons after mAb IN-1 treatment in normal rats. (A) Quantification of the total
number of branches within the apical and basilar arbors showing the mean of seven neurons per animal for each treatment group: stroke/mAb IN-1 (n5 6), mAb IN-1 only (two-
week survival; n5 4), mAb IN-1 only (six-week survival; n5 3), control Ab only (two-week survival; n5 4) and control Ab only (six-week survival; n5 3). (B) Quantification of total
dendritic length showing the mean of seven neurons per animal for each treatment group: stroke/mAb IN-1 (n5 6), mAb IN-1 only (two-week survival; n5 4), mAb IN-1 only (six-
week survival; n5 3), control Ab only (two-week survival; n5 4) and control Ab only (six-week survival; n5 3). (C) Quantification of basilar and apical spine density from a terminal
branch segment showing the mean of seven branch segments per animal for each treatment group: stroke/mAb IN-1 (n5 6), mAb IN-1 only (two-week survival; n5 4), mAb IN-1
only (six-week survival; n 5 3). All data are represented as mean ± SEM. **P\ 0.01; ***P\ 0.001 (one-way ANOVA, Newman--Keuls test for post hoc comparison).
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is not due to the intrinsic properties of motor neurons, but most
likely has some relationship to the location in the contralesional
motor cortex. The increased plasticity is speciﬁc to the
contralesional forelimb motor cortex, a region directly affected
by injury-related factors needed for guidance, attraction and
stabilization. These results support the notion of lesion-induced
events playing an important role in the stable remodeling of
dendrites after mAb IN-1 treatment.
The role of myelin-associated Nogo-A in axonal growth
inhibition is well established. We now show a role for Nogo-A,
which is present in CNS myelin and certain neuronal subtypes
(Dodd et al., 2005), including layer V and layers II/III pyramidal
neurons (Huber et al., 2002; this study), in dendritic growth
restriction as well. Treatment with mAb IN-1 to neutralize
Nogo-A may contribute to the plasticity of the system through
the orchestration of the same growth promoting mechanisms in
axons and dendrites and their subsequent stabilization. This
combination of axonal sprouting to deafferented targets and
increased dendritic arborization in the contralesional cortex
following ischemic stroke and mAb IN-1 treatment most likely
contributes to the dramatic functional recovery as reported
after anti-Nogo-A therapy.
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